NCT03286816), for which we analysed data obtained within the control arm (for study design and endpoints, see [4] ). The study was approved by the local institutional review board of Radboud University Medical Center and all study participants gave written informed consent before participation. All participants had normal awareness of hypoglycaemia (assessed by the Dutch version of the Cox questionnaire and normal counter-regulatory responses to the hypoglycaemic clamp).
Participants underwent a two-step euglycaemic (5.0 mmol/l)-hypoglycaemic (2.8 mmol/l) glucose clamp. At the end of each glycaemic phase, blood was drawn for flow cytometry and to determine catecholamine levels. Undiluted blood (50 μl, BD Vacutainer K2E [EDTA], BD, Plymouth, UK) was incubated for 15 min at room temperature in the dark with the following antibodies (all mouse): CD16-FITC (dilution 1:5), CD56-PE (1:10) (BD Biosciences, Vianen, the Netherlands); CD14-ECD (1:10), CD3-ECD (1:10), CD3-PE (1:5), CD45-PECy7 (1:50), CD8-ECD (1:10), HLA-DRPECy5 (1:10) (Beckman Coulter, Woerden, the Netherlands); CD4-PECy7 (1:20) (ITK Diagnostics BV, Uithoorn, the Netherlands). After the addition of 1 ml lysis buffer (BD Pharm Lyse, BD Biosciences), samples were mixed, incubated for another 10 min and finally measured on a Beckman Coulter FC500 flow cytometer. Single staining and fluorescence-minus-one control stains were used to determine the position of analysis gates. Flow cytometry data were analysed using Kaluza software (Beckman Coulter). Immune cell subset numbers were calculated based on percentages measured with flow cytometry and cell numbers from blood differentials measured on a Sysmex XN-450 (Sysmex, EttenLeur, the Netherlands). A Spearman's rank sum test was used for correlation analysis. Wilcoxon signed rank test was used to test differences between two related samples. All data are expressed as mean ± SD. A p value of <0.05 was considered statistically significant. Statistical analyses were performed with SPSS version 22 (IBM, Armonk, NY, USA).
Glucose levels during the euglycaemic-hypoglycaemic clamp were maintained at 5.2 ± 0.2 and 2.8 ± 0.1 mmol/l, respectively. Hypoglycaemia significantly increased adrenaline levels from 0.30 ± 0.19 to 3.40 ± 2.27 nmol/l (p = 0.018). As expected, hypoglycaemia increased leucocyte counts (Fig. 1a) , which was predominantly due to increased numbers and relative percentages of lymphocytes and monocytes, but not neutrophils (Fig. 1b-g ).
Elevated lymphocyte counts were mainly due to increased numbers of CD8 + T cells (Fig. 1i) , which was reflected in decreased percentages of CD4 + and increased percentages of CD8 + T cells (Fig. 1j, k) . Increased percentages of CD8 + T cells during hypoglycaemia were correlated with the increase in adrenaline levels (r = 0.786, p = 0.036). Additionally, hypoglycaemia increased numbers and percentages of NKT cells and CD16 + CD56 dim cytotoxic NK cells (Fig. 1l-o (Fig. 1p, q) . However, percentages of non-classical monocytes increased, while percentages of classical monocytes decreased (Fig. 1s, t) . The ratio of classical monocytes measured under hypoglycaemic vs euglycaemic conditions was negatively correlated with the increase in adrenaline levels (r = −0.857, p = 0.014).
Increased percentages of CD8 + T cells in response to hypoglycaemia are in line with previous studies demonstrating increased gene expression of CD8A in PBMCs during hypoglycaemia [1] and are likely to be caused by increased adrenaline levels [3] . Although CD8 + T cells are atheroprotective in some situations, several pro-atherogenic effects have been demonstrated [5] . Increases in NK and NKT cells might also contribute to cardiovascular disease. NK cells were found in atherosclerotic lesions, where they increase lesion size by release of perforin and granzyme B [6] . Similarly, increased numbers of NKT cells, which can recognise lipid antigens presented via CD1d, have been observed in atherosclerotic lesions [7] .
Monocyte-derived macrophages, the most abundant cells in atherosclerotic plaques, differentiate into foam cells and contribute to plaque instability. Different monocyte subsets-classical, non-classical and intermediate-have distinct inflammatory and functional properties. Although all subsets have been related to cardiovascular disease risk, there is more evidence supporting the importance of non-classical and intermediate monocytes in the development of cardiovascular disease [8] . Hypoglycaemia-induced monocytosis was mainly driven by an increase in non-classical monocytes. This may explain increased cytokine production of monocytes isolated during hypoglycaemia vs euglycaemia [1] , since non-classical monocytes produce more proinflammatory cytokines [9] .
The clinical implications of our findings depend on various factors and require further investigation. First, recruitment of immune cells may differ between individuals with type 1 vs type 2 diabetes and between moderate vs severe hypoglycaemia. Additionally, the persistence of the effect on changes in circulating immune cell populations is currently unknown. The timeframe over which the distribution and function of the immune cell populations return, and whether this depends on the recurrence of hypoglycaemia, remain to be determined. Frequent hypoglycaemic events may indeed induce chronic inflammation, but the reduced catecholaminergic responses following recurrent hypoglycaemia may also have a dampening effect on inflammation. Interestingly, recent studies have reported that although neuroendocrine responses were reduced by antecedent hypoglycaemia, proatherotrombotic factors were increased [10] . One may speculate that acute effects of hypoglycaemia on immune cells promote a proatherogenic state dependent on other proatherogenic factors, for example, prior exposure to (chronic) hyperglycaemia.
In conclusion, hypoglycaemia increased quantities of CD8 + T cells, cytotoxic NK and NKT cells and non-classical monocytes in people with type 1 diabetes. Our study further supports the concept that hypoglycaemia promotes acute inflammation in individuals with type 1 diabetes, which may contribute to a more chronic (sustained) proinflammatory state.
